Home › Non-Small Cell Lung Cancer › Washington › Seattle
Non-Small Cell Lung Cancer clinical trials in Seattle, WA
55 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RecruitingPhase 1/2
- Virginia Mason Medical Center, Seattle
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Swedish Medical Center-First Hill, Seattle
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
RecruitingPhase 1
- Fred Hutchinson Cancer Research Center, Seattle
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
- Virginia Mason Medical Center, Seattle
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
RecruitingPhase 3
- Local Institution - 0283, Seattle
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RecruitingPhase 3
- Swedish Cancer Institute ( Site 0143), Seattle
- St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192), Silverdale · 17 mi away
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RecruitingPhase 3
- Fred Hutchinson Cancer Center ( Site 3202), Seattle
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RecruitingPhase 3
- Local Institution - 0508, Seattle
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RecruitingPhase 3
- Swedish Medical Center-First Hill, Seattle
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecruitingPhase 3
- Swedish Medical Center, Seattle
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RecruitingPhase 1/2
- Fred Hutchinson Cancer Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Swedish Medical Center-Ballard Campus, Seattle
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Swedish Medical Center, Seattle
- VA Puget Sound Health Care System, Seattle
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
RecruitingPhase 2
- Swedish Cancer Institute, Seattle
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Research Site, Seattle
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
- Fred Hutchinson Cancer Center, Seattle
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RecruitingPhase 2
- Research Site, Seattle
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- Swedish Cancer Institute, Seattle
- Swedish Medical Center, Seattle
T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
RecruitingPhase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
SMP-3124LP in Adults With Advanced Solid Tumors
RecruitingPhase 1/2
- University of Washington, Seattle
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RecruitingPhase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Swedish Medical Center-First Hill, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Swedish Medical Center-First Hill, Seattle
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RecruitingPhase 1/2
- University of Washington Fred Hutchinson Cancer Center, Seattle
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 2/3
- Fred Hutchinson Cancer Center. /ID# 277939, Seattle
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
RecruitingPhase 3
- University of Washington - Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Swedish Medical Center, Seattle
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- University of Washington Fred Hutchinson, Seattle
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecruitingPhase 3
- Clinical Study Site, Seattle
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
RecruitingPhase 2
- Fred Hutchison Cancer Center, Seattle
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
RecruitingPhase 2
- University of Washington (Data Collection Only), Seattle
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
Recruiting
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RecruitingPhase 1
- University Of Washington, Seattle
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
RecruitingPhase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- Swedish Cancer Institute, Seattle
- Swedish Medical Center, Seattle
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 2
- Seattle Cancer Care Alliance, Seattle
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
Recruiting
- Fred Hutch/University of Washington Cancer Consortium, Seattle
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Fred Hutchinson Cancer Center, Seattle
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- and 1 more
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RecruitingPhase 1/2
- Virginia Mason Medical Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Seattle
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Fred Hutch Cancer Center, Seattle
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
RecruitingPhase 1
- Swedish Health Sciences, Seattle
- Research Site, Seattle
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX143 studies
- New York City, NY123 studies
- Arlington, VA111 studies
- Nashville, TN97 studies
- Los Angeles, CA92 studies
- Boston, MA87 studies
- St. Louis, MO68 studies
- Baltimore, MD60 studies
- San Antonio, TX60 studies
- Chicago, IL59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Seattle
- Cancer (all types)48 studies
- Prostate Cancer45 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Breast Cancer37 studies
- Colorectal Cancer35 studies
- Lung Cancer34 studies
- Ovarian Cancer29 studies
- Pancreatic Cancer22 studies
- Multiple Myeloma22 studies
- Acute Lymphoblastic Leukemia22 studies
- Chronic Lymphocytic Leukemia22 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.